Could Gut Bacteria Steal the Spermidine Your Gut Lining Needs?

Spermidine has become a longevity favourite, sold in capsules and praised in wheat germ. Most talk is about getting more of it. Our research desk asks a different question: could some of your gut bacteria be taking it away from the cells that need it?

Spermidine is a small molecule made by both microbes and our own cells. Inside cells, enzymes use it to make hypusine, a modification the protein eIF5A needs to work. Working eIF5A helps cells make TFEB, a master switch for autophagy, the process that sends damaged proteins and parts to the lysosome for recycling.

Some gut bacteria carry a transporter called PotABCD that pulls spermidine in. The desk proposes that an aging-linked rise in such bacteria, especially the family that includes E. coli, could soak up spermidine before it reaches the gut lining. That rise is an assumption: none of the four papers we cite addresses it, and we have not sourced it here. The chain would run: less spermidine in lining cells, less active eIF5A, less TFEB, weaker autophagy, and more clumped, damaged protein.

The desk gives the complete chain a 30% chance of surviving its proposed test.

Several links are well supported. In 2009, Tobias Eisenberg and colleagues reported that spermidine extended lifespan in yeast, flies and worms, and in human immune cells in culture, by inducing autophagy. In mice, that paper showed reduced oxidative stress, not longer life. A later paper from the same group, in Nature Medicine in 2016, reported that dietary spermidine extended lifespan and reduced cardiac hypertrophy in mice. None of this establishes a human longevity benefit.

The human evidence is thin. The Bruneck cohort, reported by Kiechl and colleagues in 2018, linked higher dietary spermidine intake to lower mortality, but it is observational and cannot show cause. A randomized trial called SmartAge found no cognitive benefit from spermidine supplements over 12 months in older adults at risk of dementia.

In 2019, Zhang and colleagues showed the eIF5A route in immune cells. Spermidine modifies eIF5A, which is needed to make TFEB. Older people had lower spermidine and less TFEB in B cells. Adding spermidine restored the pathway and improved responses of old human B cells.

The transporter is real. A 2010 review by Igarashi and Kashiwagi describes PotABCD as the spermidine-preferring uptake system in E. coli. It also notes an exporter, a reminder that bacteria both take in and release polyamines.

The counterpoint is strong. A 2022 review by Shin Kurihara describes gut bacteria mainly as suppliers. Their polyamines calm inflammation, support the gut barrier and pass into the blood, with mouse studies showing better cognition and longer life. The desk's idea requires some communities to flip from net supplier to net consumer.

• Unsourced premise. The age-linked rise in spermidine-importing bacteria is assumed here, not shown by our cited papers. The whole hypothesis rests on it. • Host backup. Intestinal cells make their own spermidine, and diet supplies more. • Recycling. Bacteria that die release what they absorbed. • Transfer from immune cells. The eIF5A to TFEB link was shown in B cells. The gut lining may behave differently, as the desk notes. • Confounding by inflammation. These bacteria can also inflame the gut, which damages proteins by another route. The proposed mouse test is well built. Aged germ-free mice receive the same defined community with one strain varied: normal, transporter-deficient, or restored. Diet stays fixed. Labeled spermidine tracks where the molecule goes. Restoring TFEB in gut cells would test the downstream link.

If true, the idea would shift attention from swallowing more spermidine to the gut community that handles it. It would also explain why supplement results vary between people. For now, it is a question, not a reason to act.

• Eat a varied, fibre-rich diet with legumes, whole grains, mushrooms and aged cheeses, which naturally contain polyamines. • Do not start spermidine supplements on the strength of this idea. Human longevity benefit is unproven.

• Gnotobiotic mouse studies comparing transporter-normal and transporterdeficient strains with labeled spermidine. • Human data on whether stool or tissue spermidine tracks the abundance of uptakeheavy bacteria with age, and a sourced test of whether those bacteria rise with age. • Randomized human trials of spermidine with functional, not just biomarker, outcomes.

Gene-Editing Stocks Are Priced on Future Patients, Big Pharma on Today's Cash Flow